Cargando…

Discovery of highly potent SARS-CoV-2 M(pro) inhibitors based on benzoisothiazolone scaffold

The COVID-19 pandemic has drastically impacted global economies and public health. Although vaccine development has been successful, it was not sufficient against more infectious mutant strains including the Delta variant indicating a need for alternative treatment strategies such as small molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Weixiong, Feng, Bo, Han, Sheng, Wang, Peipei, Chen, Wuhong, Zang, Yi, Li, Jia, Hu, Youhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730469/ https://www.ncbi.nlm.nih.gov/pubmed/34998903 http://dx.doi.org/10.1016/j.bmcl.2022.128526

Ejemplares similares

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Molecular Mechanism of Action of Antimalarial Benzoisothiazolones: Species-Selective Inhibitors of the Plasmodium spp. MEP Pathway enzyme, IspD
por: Price, Kathryn E., et al.
Publicado: (2016)

Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery
por: Chen, Yi, et al.
Publicado: (2020)

Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 M(pro)
por: Citarella, Andrea, et al.
Publicado: (2023)

Investigating novel thiazolyl-indazole derivatives as scaffolds for SARS-CoV-2 M(Pro) inhibitors
por: Airas, Justin, et al.
Publicado: (2022)

Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2
por: Shin, Young Sup, et al.
Publicado: (2021)

Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
por: Krüger, Nadine, et al.
Publicado: (2023)

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M(pro) inhibitor
por: Zaidman, Daniel, et al.
Publicado: (2021)

A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants
por: Huang, Chong, et al.
Publicado: (2023)

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
por: Hung, Hui-Chen, et al.
Publicado: (2020)

Discovery of SARS-CoV-2 M(pro) peptide inhibitors from modelling substrate and ligand binding
por: Chan, H. T. Henry, et al.
Publicado: (2021)

Computationally driven discovery of SARS-CoV-2 M(pro) inhibitors: from design to experimental validation
por: El Khoury, Léa, et al.
Publicado: (2022)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2
por: Shin, Young Sup, et al.
Publicado: (2023)

Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M(pro) Protease through Virtual Screening
por: Rubio-Martínez, Jaime, et al.
Publicado: (2021)

Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors
por: Cui, Jiahua, et al.
Publicado: (2021)

Cordifolioside: potent inhibitor against M(pro) of SARS-CoV-2 and immunomodulatory through human TGF-β and TNF-α
por: Manne, Munikumar, et al.
Publicado: (2021)

In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-M(Pro) inhibitors
por: Aljuhani, Ateyatallah, et al.
Publicado: (2022)

Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
por: Hicks, Emily G., et al.
Publicado: (2022)

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization
por: Mercorelli, Beatrice, et al.
Publicado: (2022)

Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents
por: Aziz, Marwa A., et al.
Publicado: (2016)

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery
por: Devine, William, et al.
Publicado: (2015)

Discovery of 4′-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor
por: Wu, Qianqian, et al.
Publicado: (2022)

Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases
por: Kühl, Nikos, et al.
Publicado: (2022)

Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups
por: Jiang, Yingnan, et al.
Publicado: (2016)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
por: Regnier, Thomas, et al.
Publicado: (2009)

Discovery of New Potent anti-MERS CoV Fusion Inhibitors
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

Luminescent Assay for the Screening of SARS‐CoV‐2 M(Pro) Inhibitors
por: Sondag, Daan, et al.
Publicado: (2022)

Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
por: Zhang, Zhimin, et al.
Publicado: (2019)

Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
por: Sun, Le-Yun, et al.
Publicado: (2021)

Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M(Pro) Inhibitor
por: Alhadrami, Hani A., et al.
Publicado: (2021)

Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro)
por: Wang, Zhengyuan, et al.
Publicado: (2021)

M(pro)-targeted anti-SARS-CoV-2 inhibitor-based drugs
por: She, Zhuxin, et al.
Publicado: (2023)

Discovery and characterization of potent And‐1 inhibitors for cancer treatment
por: Li, Jing, et al.
Publicado: (2021)

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor
por: Zu, Shulong, et al.
Publicado: (2020)

Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (M(pro))
por: Abdul-Hammed, Misbaudeen, et al.
Publicado: (2021)

Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2
por: Chen, Xiaoxin, et al.
Publicado: (2023)

A focus on the discovery of potent and selective cyclic peptide scaffolds for drug development
por: Saunders, George J., et al.
Publicado: (2022)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 M(pro)
por: Hussain, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87lleqhsid6aagoc0og6orgrfb